Trials / Completed
CompletedNCT01518309
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
An Open-Label Safety Study of Pimavanserin in Parkinson's Disease Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- ACADIA Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pimavanserin tartrate (ACP-103) | Tablets taken once daily by mouth at 20, 40, or 60 mg doses |
Timeline
- Start date
- 2004-11-17
- Primary completion
- 2013-05-02
- Completion
- 2013-05-02
- First posted
- 2012-01-26
- Last updated
- 2020-11-23
- Results posted
- 2020-11-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01518309. Inclusion in this directory is not an endorsement.